New Delhi: Drug firm Lupin Tuesday said it has launched in the US generic Imatinib Mesylate tablets used for treatment of certain types of cancer. The company's alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier for the product, Lupin said in a statement. Lupin's Imatinib Mesylate tablets, 100 mg (base) and 400 mg (base), are generic versions of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, it added.
As per IQVIA MAT May 2019 data, Imatinib Mesylate tablets, 100 mg (base) and 400 mg (base) had annual sales of around USD 548 million in the US market, Lupin said. The tablets are indicated for the treatment of various types of cancer including newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. The drug is also used for treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia, it added.
Shares of Lupin were trading at Rs 748.55 per scrip on BSE, up 2.02 per cent from the previous close.
